Nuclear Science and Techniques

《核技术》(英文版) ISSN 1001-8042 CN 31-1559/TL     2019 Impact factor 1.556

Nuclear Science and Techniques ›› 2015, Vol. 26 ›› Issue (6): 060305 doi: 10.13538/j.1001-8042/nst.26.060305

• NUCLEAR CHEMISTRY,RADIOCHEMISTRY,RADIOPHARMACEUTICALS AND NUCLEAR MEDICINE • Previous Articles     Next Articles

125I brachytherapy combined with chemotherapy of advanced non-small cell lung cancer

LIN Yuan-Qiang,1 SUN Yu ,2 WANG Ren-Jie,1 GAO Shi,1 CHEN Bin ,1 SUN Bu-Tong,3 MA Qing-Jie,1 JI Tie-Feng,1 ZHANG Hai-Shan 1   

  1. 1Department of Nuclear Medicine, China-Japan Union Hospital, Jilin University, Changchun 130033, China
    2Department of Radiology, China-Japan Union Hospital, Jilin University, Changchun 130033, China
    3Department of Oncology, China-Japan Union Hospital, Jilin University, Changchun 130033, China
  • Contact: MA Qing-Jie;ZHANG Hai-Shan E-mail:maqingjiejlu@163.com;zhanghaisjlu@163.com
PDF ShareIt Export Citation
LIN Yuan-Qiang, SUN Yu, WANG Ren-Jie, GAO Shi, CHEN Bin, SUN Bu-Tong, MA Qing-Jie, JI Tie-Feng, ZHANG Hai-Shan . 125I brachytherapy combined with chemotherapy of advanced non-small cell lung cancer.Nuclear Science and Techniques, 2015, 26(6): 060305     doi: 10.13538/j.1001-8042/nst.26.060305

Abstract:

This study was to evaluate effect of 125I brachytherapy combined with chemotherapy on advanced non-small cell lung cancer (NSCLC). Patients with NSCLC in stages III to IV were divided into two groups: Group A (n = 27) received 125I brachytherapy combined with gemcitabine and cisplatin (GP) chemotherapy, and Group B (n = 27) received GP chemotherapy only. The results showed that the overall response rate and median progression-free survival time were 78% and 11.5 months in Group A, 41% and 8 months in Group B, respectively (P < 0:05). For Group A, the 1- and 2-years survival rates were 67% and 37%, respectively, with the median survival time of 16 months, whereas the corresponding data of Group B were 48%, 22% and 11.5 months (P > 0.05). The interventional complications in Group A included 5 patients with postoperative pneumothorax and 4 patients with hemoptysis. No patients had radiation pneumonia, radiation esophagitis or esophagotracheal fistula. Chemotherapy treatment-related toxicities were not significantly different between the two groups. The relief of tumor-associated symptoms including cough, hemoptysis, chest pain, and short breath was found in both groups, without statistical difference in remission rates between Groups A and B (P > 0.05). In conclusion, 125I brachytherapy combined with chemotherapy proved to be safe and effective for treating advanced NSCLC with few complications. It improves local control rate and prolongs the progression-free survival time.

Key words: Non-small cell lung cancer, 125I brachytherapy, Chemotherapy